### Edgar Filing: ARQULE INC - Form 4

ARQULE II Form 4 February 20										
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). (Print or Type Responses)								OMB APPROVAL OMB 3235-0287 Number: January 31 Expires: January 31 Estimated average burden hours per response 0.5		
	Address of Reporting	S	Symbol	r Name <b>an</b> e LE INC [	d Ticker or AROL1	Tradii	0	5. Relationship of I Issuer		
(Last) ONE SANS FLOOR	(First) ( SOME STREET,	Middle) 3	B. Date of	f Earliest T Day/Year)				Director Officer (give t below)	t all applicable $X_{10\%} = 10\%$ itle $X_{2\%} = 0$ th below) Beneficial Ow	6 Owner er (specify
SAN FRAM	(Street) NCISCO, CA 941	F		endment, D nth/Day/Yea	ate Origina r)	1		6. Individual or Joi Applicable Line) Form filed by Or _X_ Form filed by M Person	ne Reporting Per	rson
(City)	(State)	(Zip)	Tabl	le I - Non-l	Derivative	Secur		iired, Disposed of,	or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		l Date, if	3. Transactic Code (Instr. 8)	4. Securiti por Dispose (Instr. 3, 4	(A) or	quired (A) D)	<ul> <li>5. Amount of Securities</li> <li>Beneficially</li> <li>Owned</li> <li>Following</li> <li>Reported</li> <li>Transaction(s)</li> <li>(Instr. 3 and 4)</li> </ul>	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/15/2008			Code V P	Amount 12,600 (3)	(D) A	Price \$ 5.0821	7,826,177 <u>(6)</u>	Ι	See footnotes $(1) (2)$
Common Stock	02/15/2008			Р	8,000 (4)	А	\$ 5.0821	7,834,177 <u>(6)</u>	I	See footnotes $(1) (2)$
Common Stock	02/15/2008			Р	29,000 (5)	А	\$ 5.0821	7,863,177 <u>(6)</u>	I	See footnotes $(1) (2)$
Common Stock	02/19/2008			Р	8,300 (3)	А	\$ 5.0993	7,871,477 <u>(6)</u>	Ι	See footnotes

### Edgar Filing: ARQULE INC - Form 4

							(1) (2)
Common Stock	02/19/2008	Р	5,000 (4)	A	\$ 5.0993	7,876,477 <u>(6)</u> I	See footnotes $(1)$ $(2)$
Common Stock	02/19/2008	Р	19,000 (5)	A	\$ 5.0993	7,895,477 <u>(6)</u> I	See footnotes $(1)$ $(2)$

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. onNumber of Derivative	6. Date Exerc Expiration Da (Month/Day/ e	ate	7. Titl Amou Under Securi	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene
	Derivative			Securities			(Instr.	. 3 and 4)		Owne
	Security			Acquired (A) or						Follo Repo
				Disposed						Trans
				of (D) (Instr. 3,						(Instr
				(insul 5) 4, and 5)						
								Amount		
					Date Exercisable	Expiration Date	Title	or Number of		
			Code V	(A) (D)				Shares		

# **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
BVF PARTNERS L P/IL ONE SANSOME STREET, 31ST FLOOR SAN FRANCISCO, CA 94104		Х		Indirect Beneficial Owner			
BIOTECHNOLOGY VALUE FUND L P 900 N. MICHIGAN AVE., SUITE 1100 CHICAGO, IL 60611				Direct Beneficial Owner			
BIOTECHNOLOGY VALUE FUND II LP 900 N. MICHIGAN AVE., SUITE 1100 CHICAGO, IL 60611				Direct Beneficial Owner			
				Direct Beneficial Owner			

#### Edgar Filing: ARQULE INC - Form 4

BVF INVESTMENTS LLC 900 N. MICHIGAN AVE., SUITE 110 CHICAGO, IL 60611	00						
BVF INC/IL ONE SANSOME STREET, 31ST FLC SAN FRANCISCO, CA 94104	OOR	X	Indirect Beneficial Owner				
Signatures							
BVF Partners L.P., By: BVF Inc., its GP, By: /s/ Mark N. Lampert							
<u>**</u> Signature of Reporting Person							
BIOTECHNOLOGY VALUE FUND, L.P. By: BVF Partners L.P., its GP, By: BVF Inc., By: /s/ Mark N. Lampert							
<u>**</u> Siį	gnature of Reporting Person			Date			
BIOTECHNOLOGY VALUE FUND II, L.P., By: BVF Partners L.P., its GP, By: BVF Inc., By: /s/ Mark N. Lampert							
**Signature of Reporting Person							
BVF INVESTMENTS, L.L.C., By: BVF Partners L.P., its Manager, By: BVF Inc., By: /s/ Mark N. Lampert							
<u>**</u> Siį	gnature of Reporting Person			Date			
BVF INC., By: /s/ Mark N. Lampert							
<u>**</u> Si <u>s</u>	gnature of Reporting Person			Date			

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The shares reported in this response are indirectly beneficially owned by BVF Partners L.P., a Delaware limited partnership ("Partners"), the designated filer of this joint filing on Form 4, and by its general partner, BVF Inc., a Delaware corporation ("BVF Inc."), which is also an investment advisor to Partners. Partners is the general partner of Biotechnology Value Fund, L.P., a Delaware limited partnership

(1) ("BVF, L.P.") and Biotechnology Value Fund II, L.P., a Delaware limited partnership ("BVF2, L.P."), both investment limited partnerships. Partners also is the manager of BVF Investments, L.L.C., a Delaware limited liability company ("Investments"). Pursuant to the operating agreement of Investments, Partners is authorized, among other things, to invest the funds of Ziff Asset Management, L.P., the majority member of Investments, in the shares of Common Stock reported in Table I as being beneficially owned by Investments.

Mark N. Lampert is the sole shareholder and sole director of BVF Inc., and is an officer of BVF Inc. This joint filing on Form 4 shall not(2) be deemed an admission that Mark N. Lampert is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any equity securities covered by this joint filing.

- (3) Shares directly beneficially owned by BVF, L.P.
- (4) Shares directly beneficially owned by BVF2, L.P.
- (5) Shares directly beneficially owned by Investments.
- (6) Total amount of shares indirectly beneficially owned by Partners and BVF Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.